1. What Happened? The ₩11.7 Billion Lawsuit Explained

On July 28, 2025, Amicogen was sued by Bifido for ₩11.7 billion in unpaid loans. This significant amount, equivalent to 9.5% of Amicogen’s assets, could severely impact the company’s financial health depending on the outcome of the lawsuit.

2. Why Now? Poor Performance and Macroeconomic Headwinds

Amicogen’s Q1 2025 financial report revealed declining sales and an operating loss. High debt levels are also a concern for investors. Adding to these challenges are macroeconomic headwinds, including a rising KRW/USD exchange rate, increasing interest rates, rising raw material prices, and uncertainty in the Chinese market.

3. What’s Next? Short-Term Pressure and Long-Term Uncertainty

The lawsuit is likely to put downward pressure on Amicogen’s stock price in the short term. An unfavorable outcome could further strain the company’s finances and dampen investor sentiment. However, Amicogen is pursuing long-term growth strategies, including the commercialization of 7-ACA direct production strain (DX) technology and the development of endolysin. The success of these strategies could potentially offset the negative impact of the lawsuit.

4. What Should Investors Do? Proceed with Caution and Monitor Closely

A conservative approach to investing in Amicogen is recommended at this time. Investors should carefully monitor the progress and outcome of the lawsuit, as well as the feasibility of the company’s long-term growth strategies, before making any investment decisions.